Derm-Biome’s compound prevented epidermal thickening, reduced cellular senescence and preserved collagen levels under UV stress.
Skin-focused biopharma Derm-Biome Pharmaceuticals is advancing an experimental topical compound that may offer a new approach to slowing or preventing skin aging caused by ultraviolet light. The candidate, known as DB-006, was one of three molecules recently tested by the company in a preclinical photoaging study, where it showed unexpectedly strong activity against hallmark features of sun-related skin decline.
DB-006 emerged as part of Derm-Biome’s primary mission to develop treatments for inflammatory skin diseases and skin cancers. Initially identified through the Vancouver-based company’s program focused on novel triterpenoid analogs, the compound showed early promise as a dermatology candidate, leading to its inclusion in the photoaging study.
“Over the years, we have received anecdotal and observational reports that our compounds noticeably improved the appearance of skin,” Derm-Biome founder Gord Eberwein told us in an exclusive interview. “It was these observations that were the genesis of this new study. Given the protective, preventive, and restorative effects we observed with our compounds in previous efficacy studies, we decided to test whether these beneficial activities would also extend to photoaging.”
Skin longevity potential?
The new study was designed to mimic the effects of day-to-day sun exposure, which accounts for up to 80 percent of visible skin aging. In the trial, using UVB-irradiated hairless mice, DB-006 prevented epidermal thickening, reduced the accumulation of senescent cells and preserved collagen levels that are normally degraded under chronic UV stress. Derm-Biome suggests the results indicate the compound may have potential in skin longevity.
“When skin better withstands UV damage, it experiences less DNA damage, inflammation, collagen breakdown, and cellular senescence – the processes that accelerate visible aging,” said Eberwein. “In other words, higher UV resistance translates into slower, healthier skin aging. Our compound demonstrated preventive activity against UV-induced damage, with early signals suggesting it may also promote repair of stress-related cellular dysfunction.”
According to the company, DB-006 also blunted expression of MMP-9, an enzyme linked to collagen breakdown, while boosting levels of sirtuins – enzymes tied to cellular stress response and mitochondrial health – which are typically suppressed by UV exposure. Because sirtuin activity depends on NAD+, the company suggests DB-006 may be influencing the longevity-linked metabolic pathway.
“Our current data show increased SIRT1/3/5 expression in UV-challenged skin, a pathway that is closely linked to NAD+ metabolism,” said Eberwein. “To build on this, we are conducting in vitro assays to determine whether the observed anti-inflammatory and anti-senescence effects are mediated through the NAD+/sirtuin axis.”
Further research needed
While the trial was preclinical, Derm-Biome believes DB-006 could potentially now be advanced either as a dermatological drug or a cosmeceutical ingredient.
“The data has just come in and we are absorbing it now,” said Eberwein. “The pathway for advancing a cosmeceutical does look appealing, with the potential for a quicker path to revenue and licensing opportunities, but we will need to look at all of our options.”
Looking ahead, the company now plans to refine DB-006 through formulation optimization and dosing studies to maximize solubility and efficacy, as well as conducting further research.
“Additional studies will include mitochondrial assays, 3D skin models, epigenetic studies, DNA damage assays, and formulation development,” said Eberwein. “Over the next month we will reach out to advisors and CROs for guidance on the best path forward.”
Future research will also expand beyond histological markers to functional measures such as elasticity, barrier integrity and inflammatory signaling – endpoints that more directly reflect how skin ages and responds to environmental stress.
“By measuring these endpoints, the team hopes to better understand how treatments can help protect skin and maintain its resilience over time,” said Eberwein.
While the new study results are compelling, it is still early days for Derm-Biome and DB-006. The next challenge for the company will be translating its apparent protective effects in animal models into meaningful outcomes for human skin.
